Table 2 Estimated vaccine efficacy from the November models against infection, symptomatic disease, hospital admission and death after one or two doses with either the AstraZeneca ChAdOx vaccine or an mRNA vaccine such as the Pfizer vaccine. Values are taken from UKHSA reports [65, 66]
From: An assessment of the vaccination of school-aged children in England against SARS-CoV-2
Protection against: | AstraZeneca | Pfizer | ||
|---|---|---|---|---|
| Â | Dose 1 | Dose 2 | Dose 1 | Dose 2 |
Infection | 45% | 70% | 55% | 85% |
Symptoms | 45% | 70% | 55% | 90% |
Hospitalisation | 80% | 95% | 80% | 95% |
Deaths | 80% | 98% | 80% | 98% |